Navigating UnitedHealthcare Ajovy Prior Authorization

Ajovy (Fremanezumab) Coverage with UnitedHealthcare

Ajovy (fremanezumab) is a CGRP inhibitor indicated for the preventive treatment of migraine in adults, representing a high-volume target for prior authorization across commercial, Medicare Advantage, and Medicaid managed care plans. UnitedHealthcare's coverage for specialty injectables like Ajovy often routes through OptumRx for the pharmacy benefit, while medical benefit submissions are handled separately.

UnitedHealthcare Prior Authorization Submission Channels for Ajovy

• For medical benefit Ajovy, submissions are primarily directed through the UnitedHealthcare Provider Portal at uhcprovider.com, utilizing the Prior Authorization and Notification tool.
• X12 278 transactions are supported via clearinghouses for medical benefit prior authorizations, aligning with established electronic data interchange standards.
• For pharmacy benefit Ajovy, OptumRx manages prior authorizations, with submissions accepted through OptumRx's provider PA system and via ePA partners like CoverMyMeds and Surescripts.
• Verify whether Ajovy falls under the medical or pharmacy benefit by consulting UnitedHealthcare's current Specialty Pharmacy Drug Program list, as this split is therapeutic-class specific.

Understanding UnitedHealthcare's Medical Necessity Criteria for Ajovy

UnitedHealthcare publishes its medical necessity criteria and coverage rules through its public Medical Policy Library. For Ajovy, these policies define clinical indications, step therapy requirements, and other utilization management guidelines that must be met for approval. Organizations should reference the specific policy number and effective date.

Common Denial Patterns for Ajovy Prior Authorizations with UnitedHealthcare

• **Medical Necessity / Insufficient Clinical Documentation:** Failure to provide adequate clinical evidence supporting the diagnosis or treatment plan, or not meeting UHC's specific criteria for migraine prophylaxis.
• **Step Therapy Requirements:** Lack of documentation demonstrating prior failure or contraindication to required preceding therapies as outlined in UHC's formulary or medical policies.
• **Non-Formulary Drug:** If Ajovy is not on the specific plan's formulary, or if a preferred alternative is available and not attempted.
• **Off-Label Use:** Prescribing Ajovy for an indication not approved by the FDA or lacking sufficient compendium support recognized by UHC.

Streamlining Ajovy Prior Authorization with Klivira's Platform

Klivira's prior authorization automation platform integrates directly with EMRs and payer portals like uhcprovider.com, as well as ePA partners such as CoverMyMeds and Surescripts. This connectivity streamlines the submission process for UnitedHealthcare Ajovy prior authorizations, helping to reduce manual effort and accelerate decision times.

UnitedHealthcare's Electronic Prior Authorization (ePA) and Turnaround Times

UnitedHealthcare is an active participant in the HL7 Da Vinci Project, signaling its commitment to advancing electronic prior authorization standards, including Da Vinci PAS. For pharmacy benefit Ajovy, ePA is supported through OptumRx via CoverMyMeds and Surescripts. Turnaround times are governed by state insurance regulations for commercial plans and by CMS-0057-F for Medicare Advantage and UnitedHealthcare Community Plan lines, requiring 72-hour standard and 24-hour expedited decisions on a phased compliance timeline.